Literature DB >> 2018756

Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies.

A H Wang1, Y G Gao, Y C Liaw, Y K Li.   

Abstract

Formaldehyde (HCHO) cross-links the anticancer drug daunorubicin (DAU) to DNA efficiently. When DAU is mixed with DNA hexamers, d(CGCGCG) and d(CGTDCG), in the presence of HCHO, stable covalent adducts of DNA are formed, as shown by the HPLC analyses. The major adducts are identical with the materials in the respective crystals which can be readily obtained from the 1:1 mixture of DAU-d(CGCGCG) and DAU-d(CGTDCG) plus HCHO, but not from the solution without HCHO. The high-resolution (1.5 A) X-ray crystal structure of those adducts shows unambiguously that they contain a covalent methylene bridge between the N3' of daunosamine and the N2 of the guanine or 2-aminoadenine. The perfect juxtaposition of the two amino groups in the minor groove of the complex provides a template for an efficient addition of HCHO. The methylene bridge does not perturb the conformation of the drug-DNA complex, when compared to the structure of DAU-d(CGTACG). The results suggest new approaches for synthesizing a new type of potential anticancer drug by attaching a reactive (e.g., alkylating) functional group at the N3' amino position of daunorubicin/doxorubicin. The stable drug-DNA adduct may be useful as probes for other biological studies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2018756     DOI: 10.1021/bi00230a002

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  22 in total

1.  The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes.

Authors:  Claudia Temperini; Luigi Messori; Pierluigi Orioli; Cristina Di Bugno; Fabio Animati; Giovanni Ughetto
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

Review 2.  DNA repair and personalized breast cancer therapy.

Authors:  Shu-Xia Li; Ashley Sjolund; Lyndsay Harris; Joann B Sweasy
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

3.  Binding of the modified daunorubicin WP401 adjacent to a T-G base pair induces the reverse Watson-Crick conformation: crystal structures of the WP401-TGGCCG and WP401-CGG[br5C]CG complexes.

Authors:  R Dutta; Y G Gao; W Priebe; A H Wang
Journal:  Nucleic Acids Res       Date:  1998-06-15       Impact factor: 16.971

4.  Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells.

Authors:  C Cullinane; S M Cutts; C Panousis; D R Phillips
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

Review 5.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

6.  Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo.

Authors:  R Sakai; K L Rinehart; Y Guan; A H Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

7.  Crystallographic studies of metal ion-DNA interactions: different binding modes of cobalt(II), copper(II) and barium(II) to N7 of guanines in Z-DNA and a drug-DNA complex.

Authors:  Y G Gao; M Sriram; A H Wang
Journal:  Nucleic Acids Res       Date:  1993-08-25       Impact factor: 16.971

8.  Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.

Authors:  Brian T Kalet; Meagan B McBryde; Joaquin M Espinosa; Tad H Koch
Journal:  J Med Chem       Date:  2007-08-16       Impact factor: 7.446

9.  A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues.

Authors:  Andrew T Lucas; Sara K O'Neal; Charlene M Santos; Taylor F White; William C Zamboni
Journal:  J Pharm Biomed Anal       Date:  2015-11-28       Impact factor: 3.935

Review 10.  Structure-based DNA-targeting strategies with small molecule ligands for drug discovery.

Authors:  Jia Sheng; Jianhua Gan; Zhen Huang
Journal:  Med Res Rev       Date:  2013-04-30       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.